What Has Been the Growth Trajectory of the Myocardial Infarction Market?
The myocardial infarction market has seen considerable growth due to a variety of factors.
•In previous years, the myocardial infarction market has seen a robust increase in its size. The current prediction is that it will escalate from $2.05 billion in 2024 to $2.2 billion in 2025, witnessed a compound annual growth rate (CAGR) of 7.2%.
This growth in the earlier period is due to factors such as the introduction of beta-blockers, the establishment of specialized chest pain centers, thrombolytic therapies, the advent of personalized medicine methodologies, and the popularity of wearable cardiovascular devices.
What Does the Future Hold for the Myocardial Infarction Market?
The myocardial infarction market is expected to maintain its strong growth trajectory in upcoming years.
• Anticipated robust expansion is on the horizon for the myocardial infarction market. It's projected to surge to $2.94 billion by 2029, with a compound annual growth rate (CAGR) of 7.5%.
This predicted growth during the forecast timeframe is attributed to worldwide initiatives for heart health, increased access to reperfusion treatments, the emergence of RNA therapeutics for cardiovascular conditions, the adoption of patient-centric care models, a focus on microvascular dysfunction, and developments in bioelectronic medicine. Key trends within the forecast period encompass progress in cardiovascular imaging, cardiac surgical procedures, telemedicine enhancements, the incorporation of artificial intelligence in diagnostic procedures, the creation of digital biomarkers for risk assessment, the application of blockchain for safeguarding healthcare data, AI-enabled drug discovery, and innovative strides in cardiac rehabilitation technology.
What Main Forces Are Fueling Expansion In The Myocardial Infarction Market?
The myocardial infarction market is projected to grow due to a rise in the number of smokers. A smoker can be defined as a person who consumes cigarettes, cigars, or smokes a pipe. The presence of dangerous chemicals in cigarette smoke thickens the blood and causes clots in veins and arteries. Such blockages, precipitated by clots, can lead to myocardial infarction. According to data provided by the UK-based Office for National Statistics in September 2023, the age group between 25 and 34 years in the UK had the highest proportion of current smokers. This group constituted 16.3%, or about 1.4 million individuals, in 2022, up from 15.8% or roughly 1.3 million individuals the previous year. Hence, the escalating number of smokers is responsible for propelling the growth of the myocardial infarction market.
What Are The Primary Segments In The Global Myocardial Infarction Market?
The myocardial infarction market covered in this report is segmented –
1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb Or IIIa Inhibitors, Antithrombotic Agents, Beta-Adrenergic Blockers, Vasodilators, Angiotensin-Converting Enzyme (ACE) Inhibitors, Angiotensin-Receptor Blockers, Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor
2) By Glycoprotein IIb Or IIIa Inhibitors: Abciximab, Eptifibatide, Tirofiban
3) By Antithrombotic Agents: Heparins, Direct Oral Anticoagulants (DOACs)
4) By Beta-Adrenergic Blockers: Metoprolol, Carvedilol
5) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate
6) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Lisinopril, Enalapril
7) By Angiotensin-Receptor Blockers: Losartan, Valsartan
8) By Analgesics: Morphine, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
9) By Thrombolytics: Alteplase, Reteplase
Pre-Book The Myocardial Infarction Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The Myocardial Infarction Market?
Leading corporations in the myocardial infarction market are concentrating on the creation of new drugs, specifically anti-inflammatory ones, to establish a unique position in the industry and target cardiovascular inflammation specifically. Anti-inflammatory drugs are therapeutic substances that minimize inflammation and alleviate pain and swelling by addressing the body's immune response. For example, Agepha Pharma, a medical product manufacturer situated in Slovakia, achieved FDA approval in June 2023 for its developed drug, Lodoco (colchicine). This is the premier anti-inflammatory medication that targets the root cause of atherosclerotic cardiovascular disease. Lodoco's purpose is to decrease the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death among the adult population. The drug can work singularly or in conjunction with cholesterol-lowering medications. In a clinical trial, Lodoco, a reconstituted low-dose of colchicine, exhibited a 31% decrease in the total risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization.
Who Are the Key Players in the Myocardial Infarction Market?
Major companies operating in the myocardial infarction market include:
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche Ltd.
• Bayer AG
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Abbott Laboratories
• Boehringer Ingelheim GmbH
• Merck KGaA
• Daiichi Sankyo Co. Ltd.
• Apotex Inc.
• Siemens Healthcare Diagnostics Limited
• Annexin Pharmaceuticals AB
• Heartseed Inc.
• Par Pharmaceutical Companies Inc.
• Tenaya Therapeutics Inc.
• Idorsia Pharmaceuticals Ltd.
• Acesion Pharma ApS
• Applied Therapeutics Inc.
• Athersys Inc.
• Cardurion Pharmaceuticals Inc.
• Verve Therapeutics Inc.
• Serca Pharmaceuticals AS
What Is The Most Dominant Region In The Myocardial Infarction Market?
North America was the largest region in the myocardial infarction market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
